A systematic review on efficiency & effectiveness of combined drug and therapy with Bevacizumab in Glioblastoma

Abstract

The most frequent and deadly primary malignant cerebral tumor in adults is glioblastoma (GBM). The U.S. Food and Drug Administration has licensed Bevacizumab (BEV) for the treatment of recurrent GBM as it has been shown to increase progression-free survival (PFS). However, the treatment of glioblastoma with the use of combination regimens has been also explored. The aim of this review is to highlight the published data of current literatures and clinical trial researches on the efficacy, safety and toxicity of two or three combination of drug and therapy with Bevacizumab in the treatment of patients with recurrent and newly diagnosed GBM and analyze the outcomes. In this systematic review, through a search of PubMed and Google Scholar, published data for the most recent five years were collected. Progression free survival rate, overall survival rate, time on treatment, adverse effects and death rates were reported accordingly. A total of 15 studies (3 non-randomized (phase II) trial, 6 of randomized (phase I, II and III) trials, 3 of (phase I and II) trials, 11 of (phase II) trials, 1 (phase III) trial were retrieved for a total of 2,007 patients. Based on the available information, bevacizumab and temozolomide are known as first line treatment for glioblastoma multiform. However, there is still a shortage of relevant and sufficient information and data, bevacizumab and temozolomide based treatments are still debatable, despite the fact that certain drug combinations are frequently used in the treatment of glioblastoma.